
CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for a fixed-dose subcutaneous combination of pertuzumab (Perjeta), trastuzumab …